ADVANCES IN HUMAN BREAST AND PROSTATE CANCER

人类乳腺癌和前列腺癌今天仍然是主要的健康问题。使用目前的诊断和治疗策略，在这些疾病的死亡率方面几乎没有取得重大进展。随着真核细胞生长调控的分子、生化和细胞方面的研究产生的新信息的爆炸式增长，对这两种恶性肿瘤的发病机制已经有了重要的认识。涉及关键生长因子、生长因子受体、信号转导途径、转录因子、细胞周期调节基因和肿瘤抑制基因的遗传改变在这些疾病恶性过程的各个方面都发挥着重要作用。此外，关于非恶性组织（如血管内皮细胞和免疫细胞）在人体对癌症的反应中所起作用的知识，为针对恶性细胞以外的细胞的癌症治疗开辟了新的途径。本次研讨会旨在整合人类乳腺癌和前列腺癌基础生物学的最新知识，以及新的实验治疗方法的开发和测试。从实验室到床边的主题将贯穿整个会议，介绍和讨论关于细胞生长控制的最新基础研究，以及基于这些信息的新分子治疗策略的测试结果。讨论的主题将包括直接抑制生长调节途径中的分子的策略，通过基因治疗引入正常基因以取代对生长调节至关重要的缺失或改变的位点，通过开发新疫苗产生宿主对肿瘤特定分子的免疫反应的方法，针对恶性组织血管生成的抑制和基于类固醇激素/受体作用和类视黄醛受体在细胞分化中的最新知识的预防方法的试验。我们将重点介绍活跃的转化研究领域，将基础科学信息转化为针对乳腺癌和前列腺癌的新治疗方法。

Human breast and prostate cancer continue to be major health problems today. Few significant inroads have been made on the death rates from these diseases using current diagnostic and therapeutic strategies. With the explosion of new information generated from research on the molecular, biochemical and cellular aspects of growth regulation in eukaryotic cells, significant insights have now been developed into the pathogenesis of these two malignancies. Genetic alterations involving critical growth factors, growth factor receptors, signal transduction pathways, transcription factors, cell cycle regulatory genes and tumor suppressor genes have been now shown to play important roles in various aspects of the malignant process in these diseases. In addition, knowledge regarding the role of non-malignant tissues such as vascular endothelial and immune cells play in the body's response to cancer have opened new avenues for cancer therapeutics directed at cells other than those that are malignant. This Keystone Symposium will be designed to integrate recent knowledge on the basic biology of human breast and prostate cancer with the development and testing of new experimental therapeutics. A laboratory to bedside theme will be developed and carried through the entire meeting with presentation and discussion of the most current basic research on the control of cell growth interfaced with results from testing new molecular therapeutic strategies based on this information. The topics of discussion will include strategies involving direct inhibition of molecules in growth regulatory pathways, introduction of normal genes through gene therapy to replace deleted or altered loci critical to growth regulation, approaches designed to generate host immune responses to tumor specific molecules through new vaccine development, trials directed at inhibition of angiogenesis in malignant tissues and prevention approaches based on recent knowledge regarding steroid hormone/receptor action and retinoid receptors in cell differentiation. We will highlight the exciting and very real area of active translational research, moving basic science information into new therapeutic approaches against breast and prostate cancer.